Bio
Branimir I. (Brandy) Sikic, M. D., is Professor of Medicine in the Division of Oncology at Stanford University School of Medicine. He was Director of the General Clinical Research Center and then Co-director of the Stanford University Center for Clinical and Translational Education and Research (Spectrum) and Director of the Stanford Clinical and Translational Research Unit (CTRU) from 1992-2017. He received his undergraduate education at Georgetown University, and an M. D. from the University of Chicago. He returned to Georgetown for his residency in internal medicine, and performed a research fellowship in cancer pharmacology at the National Cancer Institute and in medical oncology at Georgetown prior to his appointment to the Stanford University faculty in 1979. He has authored more than 250 publications, edited two books, and is the inventor of two U.S. patents. His publications have been cited more than 13,300 times and their research impact is very high, with an h-factor of 65. He has served on several advisory committees of the National Institutes of Health, including as chairman of the Experimental Therapeutics I Study Section. In 2005-6 he chaired the Scientific Program Committee for the American Society of Clinical Oncology (ASCO), and in 2008-9 was co-chair of the Program Committee of the American Association for Cancer Research (AACR). He founded the Central European Oncology Congress, held in Opatija, Croatia, and has directed it since 1998. In 2010 he was awarded the Katarina Zrinska medal for science and medicine by the president of Croatia. Dr. Sikic is a leader in the pharmacology of anticancer drugs and the development of new cancer therapies. His laboratory and clinical research programs closed in 2018. His research spanned the spectrum from molecular and genetic approaches in cancer cells to clinical trials in cancer patients. Dr. Sikic's laboratory studied mechanisms of drug resistance in cancer cells and the development of more effective cancer therapies. He has made major contributions to understanding the problem of multidrug resistance in cancer cells, tubulin dynamicity, IAP inhibitors, and the CCL2/CCR2 pathway. His most recent clinical trials of new anticancer drugs included Phase 1 studies of antibodies activating the T-cell regulating CD27 pathway and the macrophage regulating CD47 pathway.
